Drug intelligence / Profile preview

68Ga-XACP3

Development stage: Preclinical
Lead developer: The First Hospital of Fujian Medical University
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

68Ga-XACP3 is a gallium-68 labeled radiopharmaceutical designed for positron emission tomography (PET) imaging. It specifically targets Prostatic Acid Phosphatase (ACP3), also known as Prostatic Acid Phosphatase (PAP), an enzyme that is highly expressed in prostate cancer tissue. As a diagnostic agent, 68Ga-XACP3 is intended to detect primary tumor lesions, metastases, and recurrences in patients with prostate cancer. It is being evaluated as an alternative or complement to PSMA-targeted PET imaging (such as 68Ga-PSMA), potentially offering diagnostic utility in cases where PSMA expression is low or absent.

Other names: gallium Ga 68 XACP368Ga-labeled XACP3

Targets

PAP (Prostatic acid phosphatase)

Beyond the preview

Go deeper on 68Ga-XACP3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-XACP3.

Explore the full profile